To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
$5,300
BUY NOW
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Stem cell therapy Market size was valued at USD 12.11 Billion in 2022 and is poised to grow from USD 13.33 Billion in 2023 to USD 28.79 Billion by 2031, at a CAGR of 10.1% during the forecast period (2024-2031). 

The Global Stem cell therapy Market is highly competitive, with several key players operating in the industry. These companies are actively involved in research and development, strategic collaborations, mergers and acquisitions, and product launches to gain a competitive edge in the market. Here are some prominent players in the stem cell therapy market. The market is dynamic and competitive, with ongoing advancements and new entrants continually shaping the landscape. It is worth noting that the competitive landscape may evolve over time as companies pursue strategic collaborations, expand their product portfolios, and introduce new therapies to address unmet medical needs. 'Novartis AG (Switzerland)', 'Pfizer Inc. (US)', 'Mesoblast Limited (Australia)', 'Celgene Corporation (a subsidiary of Bristol Myers Squibb) (US)', 'TiGenix NV (a subsidiary of Takeda Pharmaceutical Company Limited) (Belgium)', 'Gamida Cell Ltd. (Israel)', 'Vericel Corporation (US)', 'Medipost Co., Ltd. (South Korea)', 'Astellas Pharma Inc. (Japan)', 'Osiris Therapeutics, Inc. (US)', 'NuVasive, Inc. (US)', 'Cynata Therapeutics Limited (Australia)', 'Cellular Dynamics International (a subsidiary of FUJIFILM Holdings Corporation) (US)', 'Lonza Group Ltd. (Switzerland)', 'Caladrius Biosciences, Inc. (US)', 'Athersys, Inc. (US)', 'Cytori Therapeutics, Inc. (US)', 'Holostem Terapie Avanzate S.r.l. (Italy)', 'Pluristem Therapeutics Inc. (Israel)', 'BioTime, Inc. (US)'

The rising burden of chronic diseases, such as cardiovascular disorders, neurodegenerative conditions, and orthopedic injuries, is a significant driver for the stem cell therapy market. Stem cell therapies offer the potential to regenerate damaged tissues and organs, providing new treatment options for patients with limited or no effective alternatives.

Increased Focus on Allogeneic Therapies: Allogeneic stem cell therapies, which use cells from a donor, have gained traction in the market. This approach offers advantages such as standardized and readily available cell sources, reduced manufacturing costs, and potential off-the-shelf treatments. Many companies are shifting their focus towards developing allogeneic cell therapy products, leading to an expanding pipeline of clinical trials and product development in this area.

In 2022, North America dominated the stem cell therapy market with the largest revenue share of 44.56%. This can be attributed to several factors, including the presence of innovative companies and key market players in the region, leading to a higher penetration of stem cell therapy products. North America is known for its strong biotechnology industry, extensive research and development activities, and a focus on promoting personalized medicines. These factors contribute to the region's leading position in the market. Additionally, the growth in North America is further supported by government initiatives aimed at promoting stem cell therapies.

Feedback From Our Clients

Global Stem Cell Therapy Market

Product ID: SQMIG35H2162

$5,300
BUY NOW